Literature DB >> 9141541

Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism.

W R Litchfield1, C Coolidge, P Silva, R P Lifton, F Fallo, G H Williams, R G Dluhy.   

Abstract

Unlike other forms of primary aldosteronism, recent prospective studies have paradoxically revealed that glucocorticoid-remediable aldosteronism (GRA) is usually characterized by normal potassium (K+) levels. To evaluate this paradox we studied 10 GRA subjects and 14 healthy controls in two protocols: 1) the renal K+ excretory response to acute oral administration of 50 mmol K+ chloride and to fludrocortisone, 0.2 mg p.o. q12 h x 4 doses; and 2) the aldosterone response to administration of 50 mmol K+ chloride. The K+ excretion rate (KER) in GRA subjects (n = 6) at baseline (45.6 +/- 8.3 microEq/min), after K+ (134 +/- 34.2 microEq/min), and after fludrocortisone (100 +/- 35.0 microEq/min) was not significantly different than that seen in the control (n = 8) subjects (54.9 +/- 19.0, 154 +/- 35.5, 112 +/- 45.8 microEq/min, respectively). Thus the renal kaliuretic response to K+ ingestion and exogenous mineralocorticoid is normal in GRA. Serum aldosterone increased from 5.0 +/- 3.8 at baseline to a maximum of 13.1 +/- 6.6 ng/dL 60 min after K+ ingestion in control subjects (n = 7), but failed to increase in GRA subjects (n = 14), going from 8.7 +/- 3.8 (baseline) to 8.8 +/- 5.4 ng/dL at 60 min (P = 0.004 vs. control). The blunted aldosterone response to K+ in GRA in association with the sharp diurnal decline in aldosterone in this ACTH-regulated syndrome probably results in a milder degree of hyperaldosteronism compared with other forms of primary aldosteronism, thereby producing volume expansion with minimal renal K+ wasting.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  1997        PMID: 9141541     DOI: 10.1210/jcem.82.5.3964

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Investigation of hypertension and the recognition of monogenic hypertension.

Authors:  D V Milford
Journal:  Arch Dis Child       Date:  1999-11       Impact factor: 3.791

2.  Monogenic forms of low-renin hypertension: clinical and molecular insights.

Authors:  Priyanka Khandelwal; Jaap Deinum
Journal:  Pediatr Nephrol       Date:  2021-08-20       Impact factor: 3.651

3.  Mild Clinical Phenotype in an 8-Year-Old Boy with Pseudohypoaldosteronism Type 2E: A Diagnostic Challenge.

Authors:  Bobbity Deepthi; Sriram Krishnamurthy; Sudarsan Krishnasamy
Journal:  Indian J Pediatr       Date:  2022-09-27       Impact factor: 5.319

Review 4.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

Review 5.  Differential diagnosis of primary aldosteronism subtypes.

Authors:  Paolo Mulatero; Chiara Bertello; Andrea Verhovez; Denis Rossato; Giuseppe Giraudo; Giulio Mengozzi; Giorgio Limerutti; Eleonora Avenatti; Davide Tizzani; Franco Veglio
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

Review 6.  Primary Aldosteronism Diagnosis and Management: A Clinical Approach.

Authors:  Gregory L Hundemer; Anand Vaidya
Journal:  Endocrinol Metab Clin North Am       Date:  2019-12       Impact factor: 4.741

7.  A clinical prediction score for diagnosing unilateral primary aldosteronism may not be generalizable.

Authors:  Erik S Venos; Benny So; Valerian C Dias; Adrian Harvey; Janice L Pasieka; Gregory A Kline
Journal:  BMC Endocr Disord       Date:  2014-12-11       Impact factor: 2.763

Review 8.  Recent Development toward the Next Clinical Practice of Primary Aldosteronism: A Literature Review.

Authors:  Yuta Tezuka; Yuto Yamazaki; Yasuhiro Nakamura; Hironobu Sasano; Fumitoshi Satoh
Journal:  Biomedicines       Date:  2021-03-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.